Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Shalom Lerrer"'
Autor:
Johanna Straube, Shoiab Bukhari, Shalom Lerrer, Robert J. Winchester, Yevgeniya Gartshteyn, Brian S. Henick, Matthew A. Dragovich, Adam Mor
Publikováno v:
Arthritis Research & Therapy, Vol 26, Iss 1, Pp 1-14 (2024)
Abstract Background PD-1 is an immune checkpoint on T cells, and interventions to block this receptor result in T cell activation and enhanced immune response to tumors and pathogens. Reciprocally, despite a decade of research, approaches to treat au
Externí odkaz:
https://doaj.org/article/bc6d198d04174195b30729ebf2594728
Autor:
Brian S Henick, Xizi Hu, Shoiab M Bukhari, Carly Tymm, Kieran Adam, Shalom Lerrer, Robert J Winchester, Adam Mor
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Background Immune checkpoint inhibitors (ICIs) have improved outcomes and extended patient survival in several tumor types. However, ICIs often induce immune-related adverse events (irAEs) that warrant therapy cessation, thereby limiting the overall
Externí odkaz:
https://doaj.org/article/ff1fa2cc84b64b689bab96d49de5afa5
Autor:
Yevgeniya Gartshteyn, Laura Geraldino-Pardilla, Leila Khalili, Shoiab Bukhari, Shalom Lerrer, Robert J. Winchester, Anca D. Askanase, Adam Mor
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionT follicular (TFH) and peripheral helper (TPH) cells have been increasingly recognized as a pathogenic subset of CD4 T cells in systemic lupus erythematosus (SLE). The SLAM Associated Protein (SAP) regulates TFH and TPH function by bindin
Externí odkaz:
https://doaj.org/article/9472196aebd24e58ae4d977933d4b805
Publikováno v:
iScience, Vol 24, Iss 9, Pp 103020- (2021)
Summary: Despite the obvious inhibitory outcome of PD-1 signaling, an additional series of functions are activated. We have observed that T cells stimulated through the T cell receptor (TCR) and PD-1 primarily do not proliferate; however, there is a
Externí odkaz:
https://doaj.org/article/ad4611e681ec4299af2a0f3e9580172c
Autor:
Yulia Liubomirski, Shalom Lerrer, Tsipi Meshel, Linor Rubinstein-Achiasaf, Dina Morein, Stefan Wiemann, Cindy Körner, Adit Ben-Baruch
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
The tumor microenvironment (TME) plays key roles in promoting disease progression in the aggressive triple-negative subtype of breast cancer (TNBC; Basal/Basal-like). Here, we took an integrative approach and determined the impact of tumor-stroma-inf
Externí odkaz:
https://doaj.org/article/a9f65fa008dd42b1b6a60b2fb18adc92
Autor:
Yulia Liubomirski, Shalom Lerrer, Tsipi Meshel, Dina Morein, Linor Rubinstein-Achiasaf, David Sprinzak, Stefan Wiemann, Cindy Körner, Marcelo Ehrlich, Adit Ben-Baruch
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Stromal cells and pro-inflammatory cytokines play key roles in promoting the aggressiveness of triple-negative breast cancers (TNBC; Basal/Basal-like). In our previous study we demonstrated that stimulation of TNBC and mesenchymal stem cells (MSCs) c
Externí odkaz:
https://doaj.org/article/18c8d3f7d7354e489e022ec3def690de
Autor:
Shalom Lerrer, Yulia Liubomirski, Alexander Bott, Khalid Abnaof, Nino Oren, Afsheen Yousaf, Cindy Körner, Tsipi Meshel, Stefan Wiemann, Adit Ben-Baruch
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
High plasticity is a hallmark of mesenchymal stem cells (MSCs), and as such, their differentiation and activities may be shaped by factors of their microenvironment. Bones, tumors, and cardiomyopathy are examples of niches and conditions that contain
Externí odkaz:
https://doaj.org/article/9ab8e668f10949c3b702a8b8149bcf1b
Autor:
Sabina Sandigursky, Adam Mor, Johanna Straube, Marianne Strazza, Kieran Adam, Shalom Lerrer, Beatrix Ueberheide
Publikováno v:
Inflammation
PD-1 is a critical therapeutic target in cancer immunotherapy and antibodies blocking PD-1 are approved for multiple types of malignancies. The phosphatase SHP2 is the main effector mediating PD-1 downstream signaling and accordingly attempts have be
Autor:
Shoiab Bukhari, Brian S. Henick, Robert J. Winchester, Shalom Lerrer, Kieran Adam, Yevgeniya Gartshteyn, Rohan Maniar, Ziyan Lin, Alireza Khodadadi-Jamayran, Aristotelis Tsirigos, Mary M. Salvatore, Galina G. Lagos, Steven L. Reiner, Matthew C. Dallos, Matthen Mathew, Naiyer A. Rizvi, Adam Mor
Publikováno v:
Cell reports. Medicine.
PD-1 is an inhibitory receptor in T cells, and antibodies that block its interaction with ligands augment anti-tumor immune responses. The clinical potential of these agents is limited by the fact that half of all patients develop immune-related adve
Autor:
Elliot A. Philips, Benjamin G. Neel, Beatrix Ueberheide, Kieran Adam, Anna S. Tocheva, Marianne Strazza, Adam Mor, Inbar Azoulay-Alfaguter, Shalom Lerrer, Connor Foster, Michael Peled, Shruti Nayak
Publikováno v:
The Journal of Biological Chemistry
Programmed cell death protein 1 (PD-1) is a critical inhibitory receptor that limits excessive T cell responses. Cancer cells have evolved to evade these immunoregulatory mechanisms by upregulating PD-1 ligands and preventing T cell–mediated anti-t